WeTrials
Recruiting

Phase II Study of the Combination of Blinatumomab and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)

What is this study?

This clinical trial is testing a combination of different cancer-fighting drugs for a fast-growing type of blood cancer called acute lymphoblastic leukemia. Researchers want to see if using immunotherapy, targeted therapy, and chemotherapy together works better to fight the cancer cells.

Who can participate?

You may be able to join if you are 18 or older, have a specific type of leukemia with certain genetic changes, and are able to take care of yourself. There are some health restrictions, such as not having uncontrolled infections or certain pancreas issues.

What will happen?

Participants will receive a combination of medications designed to help the body's immune system, stop cancer cells from growing, and block signals that help tumors spread. Your care team will monitor you closely throughout the treatment process.

Where and when?

This study is currently recruiting participants in Houston, Texas, United States. Talk to your doctor to see if this location works for you.

Key Points
  • 1Tests a combination of immunotherapy, targeted therapy, and chemotherapy
  • 2For adults with specific types of fast-growing blood cancers
  • 3Currently active and recruiting patients in Houston, Texas

Related videos

2

VJHemOnc: Dr. Nicholas Short on updated results from this trial (December 2024)

OncLive: Dr. Hannah Goulart on long-term follow-up of this trial at ASH 2025 (December 2025)

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Lymphoblastic LeukemiaBCR-ABL1 Fusion Protein ExpressionBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositivePhiladelphia Chromosome PositiveRecurrent Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic Leukemiat(9;22)

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.